Stockscreener 앱 받기
4.225
11.24%
-0.535
시간 외 거래:
4.36
0.135
+3.20%
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Canada
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000 Growth Benchmark - marketscreener.com
If you're not following me on stocktwits you probably should My money is on a partnership with Madrigal - Moomoo
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
GALTGalectin Therapeutics Inc Revenue Breakdown - Finviz
$Galectin Therapeutics (GALT.US)$ The FIB Strikes Again!! - Moomoo
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
PHPN Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics(GALT) Stock Options Chain | Quotes & News - Moomoo
FDA alignment reduces risk for Galectin Therapeutics' belapectin Phase 3 trial, keeping it a buy. - Pluang
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
1.36%
2.75%
자본화:
|
볼륨(24시간):